id,sentences,label,sentences_tokens,cuis
0,18 ||| Introduction ||| 1.16 ||| Randomisation and masking,N,randomisation masking,C0034656|C0150112
1,48 ||| Statistical analysis ||| 3.15 ||| All authors had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.,N,authors access data study fi nal responsibility decision submit publication,C3812881|C0444454|C1511726|C0557651|C4050619|G0000000|C0678341|C0679006|C1515023|C0034036
2,70 ||| Results ||| 4.21 ||| Most treatment-emergent adverse events were judged to be mild or moderate in severity.,N,treatment-emergent adverse events judged mild moderate severity,C0039798|G0000000|C0441471|C0221191|C2945599|C0205081|C0439793
3,"11 ||| Introduction ||| 1.9 ||| Participants were randomly assigned (2:2:2:2:2:2:2:1) to 4 weeks of double-blind treatment with a nebivolol and valsartan fi xed-dose combination (5 and 80 mg/day, 5 and 160 mg/day, or 10 and 160 mg/day), nebivolol monotherapy (5 mg/day or 20 mg/day), valsartan monotherapy (80 mg/day or 160 mg/day), or placebo.",I,participants randomly assigned 2 2 2 2 2 2 2 1 4 weeks double-blind treatment nebivolol valsartan fi xed-dose combination 5 80 mg/day 5 160 mg/day 10 160 mg/day nebivolol monotherapy 5 mg/day 20 mg/day valsartan monotherapy 80 mg/day 160 mg/day placebo,C0679646|G0000000|C1516050|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C0439230|C0013072|C0039798|C0068475|C0216784|C4050619|C0178602|C0205195|G0000000|C0450371|C0439422|G0000000|C1442061|C0439422|C0450371|C1442061|C0439422|C0068475|G0000000|G0000000|C0439422|C0450371|C0439422|C0216784|G0000000|C0450371|C0439422|C1442061|C0439422|C0032042
4,78 ||| Results ||| 4.29 ||| Comparison between a fi xed-dose combination and the highest approved doses of the monotherapy components is a regulatory requirement for assessment of effi cacy and safety.,N,comparison fi xed-dose combination approved doses monotherapy components regulatory requirement assessment effi cacy safety,C1707455|C4050619|C0178602|C0205195|C0205540|C0178602|G0000000|C0449432|C0220905|C1514873|C1261322|G0000000|C1419788|C0036043
5,58 ||| Results ||| 4.9 ||| The mean diff erence in systolic blood pressure between baseline and week 8 ranged from -17·7 mm Hg (SD 15·3)   for the 10 and 160 mg/day fi xed-dose combination to −17·8 mm Hg (15·8) for the 20 and 320 mg/day fi xeddose combination; from -14·2 mm Hg (14·8) for nebivolol 10 mg/day to −15·1 mm Hg (16·5) for nebivolol 40 mg/day; and from -14·2 mm Hg (14·4) for valsartan 160 mg/day to −14·8 mm Hg (15·1) for valsartan 320 mg/day (fi gure 2B).,I,diff erence systolic blood pressure baseline week 8 ranged -177 mm hg sd 153 10 160 mg/day fi xed-dose combination 178 mm hg 158 20 320 mg/day fi xeddose combination -142 mm hg 148 nebivolol 10 mg/day 151 mm hg 165 nebivolol 40 mg/day -142 mm hg 144 valsartan 160 mg/day 148 mm hg 151 valsartan 320 mg/day fi gure 2b,G0000000|G0000000|C0039155|C0005767|C0033095|C0168634|C0332174|G0000000|C1514721|C1442061|G0000000|C0025424|C2699239|C1442061|C0450371|C1442061|C0439422|C4050619|C0178602|C0205195|C1442061|G0000000|C0025424|C1442061|C0450371|C1442061|C0439422|C4050619|G0000000|C0205195|C1442061|G0000000|C0025424|C1442061|C0068475|C0450371|C0439422|C1442061|G0000000|C0025424|C1442061|C0068475|C0450371|C0439422|C1442061|G0000000|C0025424|C1442061|C0216784|C1442061|C0439422|C1442061|G0000000|C0025424|C1442061|C0216784|C1442061|C0439422|C4050619|G0000000|C1420850
6,"59 ||| Results ||| 4.10 ||| At week 8, the fi xed-dose combination 20 and 320 mg/day group had signifi cantly greater reductions in systolic blood pressure from baseline than both nebivolol 40 mg/day (p=0·001) and valsartan 320 mg/day (p=0·0005; primary statistical comparisons); all other comparisons were also signifi cant, favouring the fi xed-dose combinations (all p<0·01).",O,week 8 fi xed-dose combination 20 320 mg/day signifi cantly reductions systolic blood pressure baseline nebivolol 40 mg/day p=0001 valsartan 320 mg/day p=00005 primary statistical comparisons comparisons signifi favouring fi xed-dose combinations p<001,C0332174|G0000000|C4050619|C0178602|C0205195|C0450371|C1442061|C0439422|G0000000|G0000000|C0301630|C0039155|C0005767|C0033095|C0168634|C0068475|C0450371|C0439422|C0369773|C0216784|C1442061|C0439422|C0369773|C0205225|C0038215|C1707455|C1707455|G0000000|G0000000|C4050619|C0178602|C0453882|C0369773
7,"96 ||| Results ||| 4.47 ||| A Diastolic blood pressure, baseline to week 8 (primary endpoint) B Systolic blood pressure, baseline to week 8 FDCFigure 2 : Changes in trough seated diastolic and systolic blood pressure from baseline to week 8 and visit by visit",I,diastolic blood pressure baseline week 8 primary endpoint systolic blood pressure baseline week 8 fdcfigure 2 trough seated diastolic systolic blood pressure baseline week 8 visit visit,C0012000|C0005767|C0033095|C0168634|C0332174|G0000000|C0205225|C2349179|C0039155|C0005767|C0033095|C0168634|C0332174|G0000000|G0000000|G0000000|C0444506|C0277814|C0012000|C0039155|C0005767|C0033095|C0168634|C0332174|G0000000|C0545082|C0545082
8,68 ||| Results ||| 4.19 ||| Findings from an exploratory post-hoc assessment suggest that the signifi cant interactions associated with the Hispanic ethnicity and age group may have been driven by a higher placebo response among Hispanics and those at least 65 years of age (fi gure 5).,N,findings exploratory post-hoc assessment signifi interactions hispanic ethnicity age driven placebo response hispanics 65 age fi gure 5,C2607943|G0000000|C0687676|C1261322|G0000000|C1704675|C0086409|C0015031|C0001779|C0013126|C0032042|C0871261|C0086409|C0450371|C0001779|C4050619|G0000000|G0000000
9,"13 ||| Introduction ||| 1.11 ||| Findings are reported according to the fi nal dose, unless stated otherwise.",N,findings reported fi nal dose stated,C2607943|C0684224|C4050619|G0000000|C0178602|C1301808
10,"20 ||| Introduction ||| 1.18 ||| After a 5-min rest period, four separate sitting blood pressure measurements were taken at drug trough (the period at the end of the dosing interval) with a 2-5 min interval between measurements.",I,5-min rest period separate sitting blood pressure measurements drug trough period dosing interval 2-5 min interval measurements,C0702093|C0035253|C0439531|C0443299|C0277814|C0005767|C0033095|C0242485|C0013227|C0444506|C0439531|G0000000|C1272706|G0000000|C0702093|C1272706|C0242485
11,"42 ||| Statistical analysis ||| 3.9 ||| Analyses of safety measures were based on the safety population, defi ned as all randomly assigned participants who took at least one dose of double-blind study drug, and fi ndings are presented as descriptive statistics.",I,analyses safety measures based safety population defi ned randomly assigned participants dose double-blind study drug fi ndings descriptive statistics,C0002778|C0036043|C0079809|C1527178|C0036043|C0032659|G0000000|C1518340|G0000000|C1516050|C0679646|C0178602|C0013072|C0557651|C0013227|C4050619|G0000000|C0678257|C0038215
12,86 ||| Results ||| 4.37 ||| The absence of a systolic blood pressure eff ect in participants at least 65 years old is probably an artifact of subdivision of the sample and the small number of participants in that category.,P,absence systolic blood pressure eff ect participants 65 artifact subdivision sample participants category,C0332197|C0039155|C0005767|C0033095|G0000000|C0013806|C0679646|C0450371|C0085089|C1273519|C0370003|C0679646|C0683312
13,"102 ||| Results ||| 4.53 ||| MAW, JB, AHG, DBB, and MP designed the study, interpreted data, and revised the manuscript.",N,maw jb ahg dbb mp designed study interpreted data revised manuscript,G0000000|C1550751|C0015506|G0000000|C0024944|C1707689|C0557651|C1285553|C1511726|C1527075|C0600659
14,"47 ||| Statistical analysis ||| 3.14 ||| Three of the authors are employees of the sponsor (DBB, MP, and WC) and provided input into the data interpretation and writing of the report; beyond that, the sponsor was not directly involved in these aspects of the study.",N,authors employees sponsor dbb mp wc provided input data interpretation writing report sponsor directly involved aspects study,C3812881|C0024752|C1711305|G0000000|C0024944|C0013123|C1999230|C1708517|C1511726|C0459471|C0043266|C0684224|C1711305|C1947931|C1314939|C1547011|C0557651
15,"50 ||| Results ||| 4.1 ||| Between Jan 6, 2012 (fi rst participant, fi rst visit), and March 15, 2013 (last participant, last visit), 4161 participants were randomly assigned to receive double-blind treatment, 4118 of whom were included in the intentionto-treat population (fi gure 1).",P,jan 6 2012 fi rst participant fi rst visit march 15 2013 participant visit 4161 participants randomly assigned receive double-blind treatment 4118 included intentionto-treat population fi gure 1,C3843934|G0000000|G0000000|C4050619|C1425219|C0679646|C4050619|C1425219|C0545082|C3829202|C0450371|G0000000|C0679646|C0545082|G0000000|C0679646|G0000000|C1516050|C1514756|C0013072|C0039798|G0000000|C0332257|C0087111|C0032659|C4050619|G0000000|G0000000
16,"34 ||| Statistical analysis ||| 3.1 ||| Assuming a diastolic blood pressure mean treatment diff erence of 2 mm Hg (SD 8) between the fi xed-dose combination 20 and 320 mg/day and the nebivolol 40 mg/day groups, and between the fi xed-dose combination 20 and 320 mg/day and the valsartan 320 mg/day groups and on the basis of pairwise t test comparisons, 500 participants would need to be randomly assigned to each active-treatment group and 250 to placebo (total 3750 participants) to provide 95% power to detect a 2 mm Hg (SD 8) treatment diff erence or greater at the two-tailed 5% signifi cance level.",O,assuming diastolic blood pressure treatment diff erence 2 mm hg sd 8 fi xed-dose combination 20 320 mg/day nebivolol 40 mg/day fi xed-dose combination 20 320 mg/day valsartan 320 mg/day basis pairwise test comparisons 500 participants randomly assigned active-treatment 250 placebo total 3750 participants provide 95% power detect 2 mm hg sd 8 treatment diff erence two-tailed 5% signifi cance level,G0000000|C0012000|C0005767|C0033095|C0039798|G0000000|G0000000|G0000000|G0000000|C0025424|C2699239|G0000000|C4050619|C0178602|C0205195|C0450371|C1442061|C0439422|C0068475|C0450371|C0439422|C4050619|C0178602|C0205195|C0450371|C1442061|C0439422|C0216784|C1442061|C0439422|C1527178|G0000000|C0022885|C1707455|C1442061|C0679646|G0000000|C1516050|C1704532|C1442061|C0032042|C0439175|G0000000|C0679646|C1999230|C0450371|C0032863|C0442726|G0000000|G0000000|C0025424|C2699239|G0000000|C0039798|G0000000|G0000000|C0205448|G0000000|G0000000|G0000000|C0441889
17,"101 ||| Results ||| 4.52 ||| TDG designed the study; collected, analysed, and interpreted data; and wrote and reviewed the manuscript.",N,tdg designed study collected analysed interpreted data wrote reviewed manuscript,C1442760|C1707689|C0557651|C1516695|G0000000|C1285553|C1511726|C0043266|C0282443|C0600659
18,3 ||| Introduction ||| 1.1 ||| The combination of two antihypertensive drugs from diff erent classes is likely to cause a greater reduction in blood pressure than would an increase in the monotherapy dose.,O,combination antihypertensive drugs diff erent classes reduction blood pressure increase monotherapy dose,C0205195|C0003364|C0013227|G0000000|G0000000|C0456387|C0301630|C0005767|C0033095|C0442805|G0000000|C0178602
19,"9 ||| Introduction ||| 1.7 ||| The institutional review boards of all participating centres approved the study protocol, informed consent form, and information sheet advertisements.",N,institutional review boards participating centres approved study protocol informed consent form sheet advertisements,C0018704|C0282443|C0972401|C0679823|C0205099|C0205540|C0557651|C0442711|C1522154|C1511481|C0348078|C2349187|C0949214
20,44 ||| Statistical analysis ||| 3.11 ||| Role of the funding source,N,role funding source,C0035820|C0243098|C0449416
21,"61 ||| Results ||| 4.12 ||| The least-squares mean diff erence in the key secondary endpoint between the fi xed-dose combination and valsartan ranged from -3·9 (95% CI -5·7 to -2·1; p<0·0001) for the 10 and 160 mg/day fi xed-dose combination compared with valsartan 160 mg/day to −3·1 (-4·9 to −1·4, p=0·0005) for the 20 and 320 mg/day fi xed-dose combination compared with valsartan 320 mg/ day.",I,least-squares diff erence key secondary endpoint fi xed-dose combination valsartan ranged -39 95% ci -57 -21 p<00001 10 160 mg/day fi xed-dose combination compared valsartan 160 mg/day 31 -49 14 p=00005 20 320 mg/day fi xed-dose combination compared valsartan 320 mg/ day,C0023189|G0000000|G0000000|G0000000|C0027627|C2349179|C4050619|C0178602|C0205195|C0216784|C1514721|C0450371|C0450371|C0008107|C0450371|C0450371|C0369773|C0450371|C1442061|C0439422|C4050619|C0178602|C0205195|C1707455|C0216784|C1442061|C0439422|C0450371|C0450371|C0450371|C0369773|C0450371|C1442061|C0439422|C4050619|C0178602|C0205195|C1707455|C0216784|C1442061|C0026410|C0332173
22,10 ||| Introduction ||| 1.8 ||| Adherence was assessed using pill counts.,I,adherence assessed pill counts,C1510802|C1516048|C0009905|C0439157
23,51 ||| Results ||| 4.2 ||| Mean demographic and clinical characteristics (table) and study completion rates (fi gure 1) were comparable between treatment groups.,N,demographic clinical characteristics table study completion rates fi gure 1 comparable treatment,C0011298|C0205210|C1521970|C0039224|C0557651|C0205197|C0871208|C4050619|G0000000|G0000000|G0000000|C0039798
24,"39 ||| Statistical analysis ||| 3.6 ||| For the key secondary effi cacy parameter, each fi xeddose combination was compared with the respective component monotherapy dose only if the primary effi cacy parameter comparison was signifi cant for the fi xed-dose combination; comparisons were based on an ANCOVA model similar to that used in the primary analysis, with the baseline systolic blood pressure value as a covariate.",N,key secondary effi cacy parameter fi xeddose combination compared respective component monotherapy dose primary effi cacy parameter comparison signifi fi xed-dose combination comparisons based ancova model primary analysis baseline systolic blood pressure covariate,G0000000|C0027627|G0000000|C1419788|C0549193|C4050619|G0000000|C0205195|C1707455|G0000000|C0449432|G0000000|C0178602|C0205225|G0000000|C1419788|C0549193|C1707455|G0000000|C4050619|C0178602|C0205195|C1707455|C1527178|C0814908|C3161035|C0205225|C0002778|C0168634|C0039155|C0005767|C0033095|G0000000
25,71 ||| Results ||| 4.22 ||| The appendix lists treatmentemergent adverse events that occurred in at least 2% of the safety population.,O,appendix lists treatmentemergent adverse events occurred 2% safety population,C0003617|C0745732|G0000000|G0000000|C0441471|C1709305|G0000000|C0036043|C0032659
26,73 ||| Results ||| 4.24 ||| None of the serious adverse events were judged to be related to treatment.,N,adverse events judged treatment,G0000000|C0441471|C0221191|C0039798
27,"14 ||| Introduction ||| 1.12 ||| The comparisons with 40 mg/day nebivolol were done to satisfy the requirement by the US FDA, as outlined in the applicable regulations 13,14 and US FDA discussions with the study sponsor, that the highest approved doses of the component monotherapy drugs are included.",P,comparisons 40 mg/day nebivolol satisfy requirement fda outlined applicable regulations 13 14 fda discussions study sponsor approved doses component monotherapy drugs included,C1707455|C0450371|C0439422|C0068475|G0000000|C1514873|C0041714|G0000000|C1272460|C0220905|C0450371|C0450371|C0041714|C0557061|C0557651|C1711305|C0205540|C0178602|C0449432|G0000000|C0013227|C0332257
28,92 ||| Results ||| 4.43 ||| This study showed the potential of a nebivolol and valsartan combination.,I,study potential nebivolol valsartan combination,C0557651|C3245505|C0068475|C0216784|C0205195
29,100 ||| Results ||| 4.51 ||| Contributors,N,contributors,G0000000
30,24 ||| Introduction ||| 1.22 ||| Blood samples for assessment of biomarker levels were also collected from substudy participants.,N,blood samples assessment biomarker levels collected substudy participants,C0005767|C0370003|C1261322|C0005516|C0441889|C1516695|G0000000|C0679646
31,27 ||| Outcomes ||| 2.1 ||| The primary effi cacy endpoint was the change in trough seated diastolic blood pressure from baseline to week 8 and the key secondary effi cacy endpoint was change in seated systolic blood pressure from baseline to week 8.,O,primary effi cacy endpoint change trough seated diastolic blood pressure baseline week 8 key secondary effi cacy endpoint change seated systolic blood pressure baseline week 8,C0205225|G0000000|C1419788|C2349179|C0392747|C0444506|C0277814|C0012000|C0005767|C0033095|C0168634|C0332174|G0000000|G0000000|C0027627|G0000000|C1419788|C2349179|C0392747|C0277814|C0039155|C0005767|C0033095|C0168634|C0332174|G0000000
32,"108 ||| Results ||| 4.59 ||| AHG has received grants, personal fees or non-fi nancial support from Forest, Novartis, Daiichi-Sankyo, Takeda, the American Society for Hypertension, and the American College of Cardiology.",P,ahg received grants personal fees non-fi nancial support forest novartis daiichi-sankyo takeda american society hypertension american college cardiology,C0015506|C1514756|C0018173|C1519021|C0015751|C1518422|G0000000|C0183683|C0086312|G0000000|G0000000|G0000000|C0596070|C0037455|C0020538|C0596070|C0557806|C0007189
33,30 ||| Outcomes ||| 2.4 ||| A post-hoc effi cacy assessment of pulse pressure from baseline to week 8 was also done.,I,post-hoc effi cacy assessment pulse pressure baseline week 8,C0687676|G0000000|C1419788|C1261322|C0232117|C0033095|C0168634|C0332174|G0000000
34,104 ||| Results ||| 4.55 ||| Declaration of interests,N,declaration,G0000000
35,"110 ||| Acknowledgments ||| 5.1 ||| Kristen Andersen, Autumn Kelly, Vojislav Pejović, Leah Richmond, and Bill Sterling of Prescott Medical Communications Group (Chicago, IL, USA) assisted with literature searches, editing, creation of graphs and tables, circulation of drafts among the authors, and formatting of the manuscript for submission.",O,kristen andersen autumn kelly vojislav pejovi leah richmond bill sterling prescott medical communications chicago il usa assisted literature searches editing creation graphs tables circulation drafts authors formatting manuscript submission,G0000000|G0000000|C0238715|G0000000|G0000000|G0000000|G0000000|G0000000|C0004895|G0000000|G0000000|C0199168|C0009452|C0008044|C0020898|C0041703|C1269765|C0023866|C1552603|C0868955|C0441513|C0681493|C0039224|C0005775|C1547277|C3812881|C1301627|C0600659|C1515022
36,"15 ||| Introduction ||| 1.13 ||| Randomisation codes were generated by the Statistical Programming Department at the Forest Research Institute (Jersey City, NJ, USA) and implemented (including the maintenance of masking) by a 24-h interactive web response system.",N,randomisation codes generated statistical programming department forest institute jersey city nj usa implemented including maintenance masking 24-h interactive web response system,C0034656|C0919279|C3146294|C0038215|G0000000|C1704729|C0086312|C0021622|C0454673|C0008848|C0027971|C0041703|G0000000|C0332257|C0024501|C0150112|C0450371|C1704675|C0282111|C0871261|C0449913
37,"33 ||| Outcomes ||| 2.7 ||| Safety and tolerability were assessed by recording adverse events and monitoring vital signs at each visit; by doing physical examinations and electrocardiograph measurements at screening, baseline, and week 8; and by measuring clinical laboratory parameters from blood and urine taken at screening, baseline, and weeks 4 and 8.",I,safety tolerability assessed recording adverse events monitoring vital signs visit physical examinations electrocardiograph measurements screening baseline week 8 measuring clinical laboratory parameters blood urine screening baseline weeks 4 8,C0036043|C3274448|C1516048|G0000000|G0000000|C0441471|C0150369|C0442732|C0220912|C0545082|C0031809|C0031809|C0013798|C0242485|C0220908|C0168634|C0332174|G0000000|C0444706|C0205210|C0022877|C0449381|C0005767|C0042036|C0220908|C0168634|C0439230|G0000000|G0000000
38,53 ||| Results ||| 4.4 ||| Adherence at each visit was at least 99% for every group.,O,adherence visit 99%,C1510802|C0545082|C0450371
39,"35 ||| Statistical analysis ||| 3.2 ||| If the study was positive, the study size would provide a further 90% power to detect a mean diff erence of 2 mm Hg (SD 8) between fi xed-dose combinations 10 and 160 mg/day and 10 and 320 mg/day and the corresponding monotherapy groups, with multiplicity adjustment using the Hochberg procedure, 15 at the twotailed 5% signifi cance level.",I,study positive study size provide 90% power detect diff erence 2 mm hg sd 8 fi xed-dose combinations 10 160 mg/day 10 320 mg/day monotherapy multiplicity adjustment hochberg procedure 15 twotailed 5% signifi cance level,C0557651|C0439178|C0557651|C0456389|C1999230|C0450371|C0032863|C0442726|G0000000|G0000000|G0000000|G0000000|C0025424|C2699239|G0000000|C4050619|C0178602|C0453882|C0450371|C1442061|C0439422|C0450371|C1442061|C0439422|G0000000|C0449822|C0376209|G0000000|C0184661|C0450371|G0000000|G0000000|G0000000|G0000000|C0441889
40,17 ||| Introduction ||| 1.15 ||| Procedures,N,procedures,C0025664
41,"109 ||| Results ||| 4.60 ||| DBB, WC, and MP are employees of Forest Research Institute.",I,dbb wc mp employees forest institute,G0000000|C0013123|C0024944|C0024752|C0086312|C0021622
42,"38 ||| Statistical analysis ||| 3.5 ||| The fi xed-dose combination 20 and 320 mg/day group was compared with the nebivolol 40 mg/day and valsartan 320 mg/day groups; if both comparisons were statistically signifi cant (p<0·05), the study was deemed to be positive and the fi xed-dose combination 10 and 160 mg/day and 10 and 320 mg/day groups were compared with their corresponding monotherapy groups, with multiplicity controlled using the Hochberg procedure 15 on the adjusted p values (ie, the maximum of p values for the comparisons of the fi xeddose combination group versus its corresponding monotherapy groups).",O,fi xed-dose combination 20 320 mg/day compared nebivolol 40 mg/day valsartan 320 mg/day comparisons statistically signifi p<005 study deemed positive fi xed-dose combination 10 160 mg/day 10 320 mg/day compared monotherapy multiplicity controlled hochberg procedure 15 adjusted values maximum values comparisons fi xeddose combination versus monotherapy,C4050619|C0178602|C0205195|C0450371|C1442061|C0439422|C1707455|C0068475|C0450371|C0439422|C0216784|C1442061|C0439422|C1707455|C0038215|G0000000|C0369773|C0557651|G0000000|C0439178|C4050619|C0178602|C0205195|C0450371|C1442061|C0439422|C0450371|C1442061|C0439422|C1707455|G0000000|C0449822|C2587213|G0000000|C0184661|C0450371|C0456081|C0042295|C0806909|C0042295|C1707455|C4050619|G0000000|C0205195|G0000000|G0000000
43,91 ||| Results ||| 4.42 ||| Interpretation,N,interpretation,C0459471
44,107 ||| Results ||| 4.58 ||| JB has received consultant fees from Forest.,N,jb received consultant fees forest,C1550751|C1514756|C0009817|C0015751|C0086312
45,"40 ||| Statistical analysis ||| 3.7 ||| All other continuous parameters were analysed using an ANCOVA model with treatment group, diabetes status, subgroup factor, and treatmentgroup-by-subgroup factor interaction as factors and baseline value as a covariate.",P,continuous parameters analysed ancova model treatment diabetes status subgroup factor treatmentgroup-by-subgroup factor interaction factors baseline covariate,C0549178|C0449381|G0000000|C0814908|C3161035|C0039798|C0011847|C0449438|C1079230|C1521761|C1079230|C1521761|C1704675|C1521761|C0168634|G0000000
46,99 ||| Results ||| 4.50 ||| 1 10 ),I,1 10,G0000000|C0450371
47,"36 ||| Statistical analysis ||| 3.3 ||| Effi cacy parameters were analysed based on the intention-to-treat population, defi ned as all randomised participants who took at least one dose of double-blind drug and had at least one diastolic blood pressure measurement after baseline, using the last-observationcarried-forward approach to impute missing data.",I,effi cacy parameters analysed based intention-to-treat population defi ned randomised participants dose double-blind drug diastolic blood pressure measurement baseline last-observationcarried-forward approach impute missing data,G0000000|C1419788|C0449381|G0000000|C1527178|C0162425|C0032659|G0000000|C1518340|G0000000|C0679646|C0178602|C0013072|C0013227|C0012000|C0005767|C0033095|C0242485|C0168634|C1517741|C0449445|C2699638|C1551393|C1511726
48,"95 ||| Results ||| 4.46 ||| Finally, a design following a perfect Latin square, similar to the one used in combination studies of nebivolol and hydrochlorothiazide, 17,18 might have provided better insight into a potential dose response of the nebivolol and valsartan combination.",I,finally design perfect latin square combination studies nebivolol hydrochlorothiazide 17 18 provided insight potential dose response nebivolol valsartan combination,G0000000|C1707689|G0000000|G0000000|C0205120|C0205195|C0947630|C0068475|C0020261|C0450371|C0450371|C1999230|C0233820|C3245505|C0178602|C0871261|C0068475|C0216784|C0205195
49,6 ||| Introduction ||| 1.4 ||| Other exclusion cirteria are listed in the appendix.,P,exclusion cirteria listed appendix,C0680251|G0000000|C0745732|C0003617
50,"19 ||| Introduction ||| 1.17 ||| Blood pressure and pulse rate were measured using an automatic monitoring device (Omron HEM-705CP, Lake Forest, IL, USA).",I,blood pressure pulse rate measured automatic monitoring device omron hem-705cp lake forest il usa,C0005767|C0033095|C0232117|C0871208|C0444706|C0205554|C0150369|C0025080|G0000000|C0019080|C0337049|C0086312|C0020898|C0041703
51,"72 ||| Results ||| 4.23 ||| During double-blind treatment, 27 serious adverse events were reported by three of 277 (1%) participants in the placebo group (spontaneous abortion, cerebrovascular accident, and transient ischaemic attack), two of 555 (<1%) in the fi xed-dose combination 10 and 160 mg/day group (ankle fracture and cerebrovascular accident), two of 555 (<1%) in the fi xed-dose combination 10 and 320 mg/day group (acute myocardial infarction and appendicitis), one of 554 (<1%) in the fi xed-dose combination 20 and 320 mg/day group (diverticulitis), two of 555 (<1%) in the nebivolol 10 mg/day group (acute pyelonephritis and syncope), four of 554 (<1%) in the nebivolol 40 mg/day group (hypotension, pancreatitis, small intestinal obstruction, and thyroid cancer), four of 555 (<1%) in the valsartan 160 mg/day group (acute respiratory failure, increased carbon dioxide, cerebral infarction, intracranial aneurysm, mental status changes, substance abuse, and suicide attempt), and fi ve of 554 (<1%) in the valsartan 320 mg/day group (acute myocardial infarction, appendicitis, atrial fi brillation, facial bone fracture, gastrointestinal haemorrhage, and pneumonia).",I,double-blind treatment 27 adverse events reported 277 1% participants placebo spontaneous abortion cerebrovascular accident transient ischaemic attack 555 <1% fi xed-dose combination 10 160 mg/day ankle fracture cerebrovascular accident 555 <1% fi xed-dose combination 10 320 mg/day acute myocardial infarction appendicitis 554 <1% fi xed-dose combination 20 320 mg/day diverticulitis 555 <1% nebivolol 10 mg/day acute pyelonephritis syncope 554 <1% nebivolol 40 mg/day hypotension pancreatitis intestinal obstruction thyroid cancer 555 <1% valsartan 160 mg/day acute respiratory failure increased carbon dioxide cerebral infarction intracranial aneurysm mental status substance abuse suicide attempt fi ve 554 <1% valsartan 320 mg/day acute myocardial infarction appendicitis atrial fi brillation facial bone fracture gastrointestinal haemorrhage pneumonia,C0013072|C0039798|C0450371|G0000000|C0441471|C0684224|C1442061|G0000000|C0679646|C0032042|C0205359|C0156543|C1880018|C0000924|C0040704|C0475224|C0277793|C1442061|G0000000|C4050619|C0178602|C0205195|C0450371|C1442061|C0439422|C0003086|C0016658|C1880018|C0000924|C1442061|G0000000|C4050619|C0178602|C0205195|C0450371|C1442061|C0439422|C0205178|C0027061|C0021308|C0003615|C1442061|G0000000|C4050619|C0178602|C0205195|C0450371|C1442061|C0439422|C0012813|C1442061|G0000000|C0068475|C0450371|C0439422|C0205178|C0034186|C0039070|C1442061|G0000000|C0068475|C0450371|C0439422|C0020649|C0030305|C0021853|C0028778|C0040132|C0006826|C1442061|G0000000|C0216784|C1442061|C0439422|C0205178|C0521346|C0231174|C0205217|C0007009|C0678717|G0000000|C0021308|C0524466|C0002940|C0229992|C0449438|C0439861|C0013146|C0038661|C1516084|C4050619|C0042469|C1442061|G0000000|C0216784|C1442061|C0439422|C0205178|C0027061|C0021308|C0003615|C0018792|C4050619|G0000000|C0015450|C0262950|C0016658|C0521362|C0019080|C0032285
52,"66 ||| Results ||| 4.17 ||| In a post-hoc analysis, the decrease in pulse pressure with the fi xed-dose combination 20 and 320 mg/day was greater than the decrease noted with nebivolol 40 mg/day (p=0·0053), but seemed to be smaller than the decrease reported with valsartan 320 mg/day (p=0·053; fi gure 4B).",N,post-hoc analysis decrease pulse pressure fi xed-dose combination 20 320 mg/day decrease nebivolol 40 mg/day p=00053 decrease reported valsartan 320 mg/day p=0053 fi gure 4b,C0687676|C0002778|C0392756|C0232117|C0033095|C4050619|C0178602|C0205195|C0450371|C1442061|C0439422|C0392756|C0068475|C0450371|C0439422|C0369773|C0392756|C0684224|C0216784|C1442061|C0439422|C0369773|C4050619|G0000000|C1420850
53,"84 ||| Results ||| 4.35 ||| The benefi ts of combining blood-pressure-lowering drugs from two diff erent drug classes for the eff ective management of hypertension have been reported in many studies, including a meta-analysis of 42 trials with a total of 11 000 participants.",O,benefi combining blood-pressure-lowering drugs diff erent drug classes eff ective management hypertension reported studies including meta-analysis 42 trials total 11 000 participants,G0000000|C0336789|C0005823|C0013227|G0000000|G0000000|C0013227|C0456387|G0000000|G0000000|C0001554|C0020538|C0684224|C0947630|C0332257|C0282458|C0450371|C0008976|C0439175|C0450371|C1442061|C0679646
54,"89 ||| Results ||| 4.40 ||| In that analysis, the combination of two drugs from separate classes (a thiazide plus a β blocker; a thiazide plus an angiotensin-converting-enzyme inhibitor; a β blocker plus an angiotensin-converting-enzyme inhibitor; a β blocker plus a calcium-channel blocker; and a calcium-channel blocker plus an angiotensin-converting-enzyme inhibitor) resulted in additive eff ects that were greater than those of a double dose of a single drug.",I,analysis combination drugs separate classes thiazide blocker thiazide angiotensin-converting-enzyme inhibitor blocker angiotensin-converting-enzyme inhibitor blocker calcium-channel blocker calcium-channel blocker angiotensin-converting-enzyme inhibitor additive eff ects double dose single drug,C0002778|C0205195|C0013227|C0443299|C0456387|C0541746|G0000000|C0541746|C0022709|C1999216|G0000000|C0022709|C1999216|G0000000|C0006685|G0000000|C0006685|G0000000|C0022709|C1999216|C0442796|G0000000|C0013806|C0205173|C0178602|C0037179|C0013227
55,75 ||| Results ||| 4.26 ||| No deaths occurred during double-blind treatment.,O,deaths occurred double-blind treatment,C0011065|C1709305|C0013072|C0039798
56,74 ||| Results ||| 4.25 ||| Two deaths occurred during the single-blind placebo run-in phase; both were deemed not related to study drug.,O,deaths occurred single-blind placebo run-in phase deemed study drug,C0011065|C1709305|C0242570|C0032042|C3274438|C0205390|G0000000|C0557651|C0013227
57,31 ||| Outcomes ||| 2.5 ||| Daytime and nighttime ABPM assessments and biomarker data will be reported separately.,N,daytime nighttime abpm assessments biomarker data reported separately,C0332169|C0240526|G0000000|C1261322|C0005516|C1511726|C0684224|G0000000
58,"97 ||| Results ||| 4.48 ||| A 24 -h ABPM diastolic blood pressure, baseline to week 8 B 24 -h ABPM systolic blood pressure, baseline to week 8 C Blood pressure control rates, baseline to week 4 Figure 3 : Changes in trough seated diastolic and systolic blood pressure in the ambulatory blood pressure monitoring substudy and blood pressure control rates between baseline and week 8",I,24 -h abpm diastolic blood pressure baseline week 8 24 -h abpm systolic blood pressure baseline week 8 blood pressure control rates baseline week 4 figure 3 trough seated diastolic systolic blood pressure ambulatory blood pressure monitoring substudy blood pressure control rates baseline week 8,C0450371|C0033727|G0000000|C0012000|C0005767|C0033095|C0168634|C0332174|G0000000|C0450371|C0033727|G0000000|C0039155|C0005767|C0033095|C0168634|C0332174|G0000000|C0005767|C0033095|C0243148|C0871208|C0168634|C0332174|G0000000|G0000000|G0000000|C0444506|C0277814|C0012000|C0039155|C0005767|C0033095|C0439841|C0005767|C0033095|C0150369|G0000000|C0005767|C0033095|C0243148|C0871208|C0168634|C0332174|G0000000
59,45 ||| Statistical analysis ||| 3.12 ||| The trial was designed jointly by the principal investigator (TDG) and the study sponsor.,N,trial designed jointly principal investigator tdg study sponsor,C0008976|C1707689|G0000000|C0205225|C0035173|C1442760|C0557651|C1711305
60,49 ||| Statistical analysis ||| 3.16 ||| ITT=intention-to-treat.,N,itt=intention-to-treat,C0162425
61,"7 ||| Introduction ||| 1.5 ||| This study was done in compliance with the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use guidelines and the US Food and Drug Administration (FDA) guidelines for good clinical practice, and in accordance with the ethical principles originating from the Declaration of Helsinki and the US FDA Code of Federal Regulations Title 21, section 312.120.",N,study compliance international conference harmonisation technical requirements registration pharmaceuticals human guidelines food drug administration fda guidelines clinical practice ethical principles originating declaration helsinki fda code federal regulations title 21 312 120,C0557651|C0009563|C1512888|C0086047|G0000000|C0449851|C1514873|C1514821|C1135440|C0086418|C0162791|C0016452|C0013227|C0001554|C0041714|C0162791|C0205210|C0237607|C0026531|G0000000|G0000000|G0000000|G0000000|C0041714|C0009219|G0000000|C0220905|C1519530|C0450371|C1442061|C1442061
62,"55 ||| Results ||| 4.6 ||| At week 8, the fi xed-dose combination 20 and 320 mg/day group had signifi cantly greater reductions in diastolic blood pressure from baseline than both nebivolol 40 mg/day (p=0·030) and valsartan 320 mg/day (p<0·0001; primary statistical comparisons); all other comparisons were also signifi cant, favouring the fi xed-dose combinations (all p<0·0001).",O,week 8 fi xed-dose combination 20 320 mg/day signifi cantly reductions diastolic blood pressure baseline nebivolol 40 mg/day p=0030 valsartan 320 mg/day p<00001 primary statistical comparisons comparisons signifi favouring fi xed-dose combinations p<00001,C0332174|G0000000|C4050619|C0178602|C0205195|C0450371|C1442061|C0439422|G0000000|G0000000|C0301630|C0012000|C0005767|C0033095|C0168634|C0068475|C0450371|C0439422|C0369773|C0216784|C1442061|C0439422|C0369773|C0205225|C0038215|C1707455|C1707455|G0000000|G0000000|C4050619|C0178602|C0453882|C0369773
63,"94 ||| Results ||| 4.45 ||| Additionally, a stron g placebo response, especially among Hispanics and participants at least 65 years old, and also among the small number of elderly participants, makes assessment of the effi cacy of the combination in those subgroups diffi cult.",I,additionally stron placebo response hispanics participants 65 elderly participants assessment effi cacy combination subgroups diffi cult,G0000000|G0000000|C0032042|C0871261|C0086409|C0679646|C0450371|C0001792|C0679646|C1261322|G0000000|C1419788|C0205195|C1079230|G0000000|C0337775
64,"98 ||| Results ||| 4.49 ||| A Pulse rate, baseline to week 8 B Pulse pressure, baseline to week 8 (post-hoc analysisFigure 4 : Mean changes in pulse rate and pulse pressure between baseline and week 8",I,pulse rate baseline week 8 pulse pressure baseline week 8 post-hoc analysisfigure 4 pulse rate pulse pressure baseline week 8,C0232117|C0871208|C0168634|C0332174|G0000000|C0232117|C0033095|C0168634|C0332174|G0000000|C0687676|G0000000|G0000000|C0232117|C0871208|C0232117|C0033095|C0168634|C0332174|G0000000
65,"41 ||| Statistical analysis ||| 3.8 ||| The analyses of binary outcomes were done using a logistic regression model with treatment group as class variable and baseline blood pressure (diastolic or systolic blood pressure, as applicable) as a covariate.",O,analyses binary outcomes logistic regression model treatment class variable baseline blood pressure diastolic systolic blood pressure applicable covariate,C0002778|C1706942|C1274040|C0242415|C0684320|C3161035|C0039798|C0456387|C0439828|C0168634|C0005767|C0033095|C0012000|C0039155|C0005767|C0033095|C1272460|G0000000
66,"43 ||| Statistical analysis ||| 3.10 ||| This study is registered with ClinicalTrials.gov, NCT01508026.",N,study registered clinicaltrials gov nct01508026,C0557651|C1514821|G0000000|C1419208|G0000000
67,"87 ||| Results ||| 4.38 ||| Data interpretation is limited by several factors, including the size of the ABPM substudy, which might have been too small to capture a signifi cant diff erence in 24-h ABPM data between the groups treated with fi xeddose combination 20 and 320 mg/day and nebivolol 40 mg/day.",N,data interpretation limited factors including size abpm substudy capture signifi diff erence 24-h abpm data treated fi xeddose combination 20 320 mg/day nebivolol 40 mg/day,C1511726|C0459471|C0439801|C1521761|C0332257|C0456389|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C0450371|G0000000|C1511726|C1522326|C4050619|G0000000|C0205195|C0450371|C1442061|C0439422|C0068475|C0450371|C0439422
68,"23 ||| Introduction ||| 1.21 ||| A 24-h ABPM was recorded from substudy participants at week 0 and week 8 using a Spacelabs 90207 (Snoqualmie, WA, USA) oscillometric device that was automatically set to measure and record blood pressure.",I,24-h abpm recorded substudy participants week 0 week 8 spacelabs 90207 snoqualmie wa usa oscillometric device automatically set measure record blood pressure,C0450371|G0000000|C0034869|G0000000|C0679646|C0332174|G0000000|C0332174|G0000000|G0000000|G0000000|C1551553|C0027366|C0041703|C0029375|C0025080|C3842331|C0036849|C0079809|C0034869|C0005767|C0033095
69,"63 ||| Results ||| 4.14 ||| In the ABPM substudy, the reduction in 24-h diastolic and systolic blood pressure at week 8 was signifi cantly greater in the fi xed-dose combination 20 and 320 mg/day group than in the valsartan 320 mg/day group, but was not signifi cantly greater than in the nebivolol 40 mg/day group (fi gure 3A and 3B).",I,abpm substudy reduction 24-h diastolic systolic blood pressure week 8 signifi cantly fi xed-dose combination 20 320 mg/day valsartan 320 mg/day signifi cantly nebivolol 40 mg/day fi gure 3a 3b,G0000000|G0000000|C0301630|C0450371|C0012000|C0039155|C0005767|C0033095|C0332174|G0000000|G0000000|G0000000|C4050619|C0178602|C0205195|C0450371|C1442061|C0439422|C0216784|C1442061|C0439422|G0000000|G0000000|C0068475|C0450371|C0439422|C4050619|G0000000|C1420849|C1420850
70,"85 ||| Results ||| 4.36 ||| Finally, post-hoc and exploratory fi ndings suggest that the nebivolol and valsartan fi xed-dose combination has a haemodynamic eff ect that includes reductions in both pulse rate and pulse pressure (consistent with pharmacological properties of individual components) 10,15 and that this combination would be eff ective in a wide variety of patients.",O,finally post-hoc exploratory fi ndings nebivolol valsartan fi xed-dose combination haemodynamic eff ect includes reductions pulse rate pulse pressure consistent pharmacological properties individual components 10 15 combination eff ective wide variety patients,G0000000|C0687676|G0000000|C4050619|G0000000|C0068475|C0216784|C4050619|C0178602|C0205195|C0019010|G0000000|C0013806|C0332257|C0301630|C0232117|C0871208|C0232117|C0033095|C0332290|C0031330|C0871161|C0027361|C0449432|C0450371|C0450371|C0205195|G0000000|G0000000|C0332464|C1883525|C0030705
71,"32 ||| Outcomes ||| 2.6 ||| Subgroup analyses for the primary and key secondary effi cacy parameters were done according to participants' sex, body-mass index (<30 kg/m² or ≥30 kg/m²), ethnic origin (Hispanic or not), race (black or non-black), baseline diastolic blood pressure category (<median or ≥median), diabetes status (yes or no), and age (<65 years or ≥65 years).",P,subgroup analyses primary key secondary effi cacy parameters participants sex body-mass <30 kg/m 30 kg/m ethnic origin hispanic race black non-black baseline diastolic blood pressure category <median median diabetes status age <65 65,C1079230|C0002778|C0205225|G0000000|C0027627|G0000000|C1419788|C0449381|C0679646|C0009253|C0518010|C0450371|C1532718|C0450371|C1532718|C0015031|C0079946|C0086409|C0034510|C0005680|C1518422|C0168634|C0012000|C0005767|C0033095|C0683312|C0549183|C0549183|C0011847|C0449438|C0001779|C0450371|C0450371
72,93 ||| Results ||| 4.44 ||| Better effi cacy and comparable tolerability of the fi xed-dose combination compared with its monotherapy components suggests that nebivolol and valsartan in combination would be an eff ective and safe treatment option for patients with hypertension but with systolic and diastolic blood pressure less than 180/110 mm Hg.,O,effi cacy comparable tolerability fi xed-dose combination compared monotherapy components suggests nebivolol valsartan combination eff ective safe treatment option patients hypertension systolic diastolic blood pressure 180/110 mm hg,G0000000|C1419788|G0000000|C3274448|C4050619|C0178602|C0205195|C1707455|G0000000|C0449432|C1705535|C0068475|C0216784|C0205195|G0000000|G0000000|G0000000|C0039798|C1518601|C0030705|C0020538|C0039155|C0012000|C0005767|C0033095|C1442061|G0000000|C0025424
73,"8 ||| Introduction ||| 1.6 ||| All enrolled participants provided voluntary, written informed consent and Health Insurance Portability and Accountability Act authorisation before participation in the study.",P,enrolled participants provided voluntary written informed consent health insurance portability accountability authorisation participation study,G0000000|C0679646|C1999230|C0439656|C0043266|C1522154|C1511481|C0018684|C0021672|C0872386|C0078889|C0680281|C0679823|C0557651
74,54 ||| Results ||| 4.5 ||| The mean diff erence in diastolic blood pressure between baseline and week 8 ranged from -14·8 mm Hg (SD 9·2) for the 10 and 160 mg/day fi xed-dose combination to −15·7 mm Hg (9·6) for the 20 and 320 mg/day fi xed-dose combination; from -12·7 mm Hg (9·0) fo r nebivolol 10 mg/day to −14·4 mm Hg (9·4) for nebivolol 40 mg/day; and from -10·8 mm Hg (9·6) for valsartan 160 mg/day to −11·2 mm Hg (9·3) for valsartan 320 mg/day (fi gure 2A).,P,diff erence diastolic blood pressure baseline week 8 ranged -148 mm hg sd 92 10 160 mg/day fi xed-dose combination 157 mm hg 96 20 320 mg/day fi xed-dose combination -127 mm hg 90 fo nebivolol 10 mg/day 144 mm hg 94 nebivolol 40 mg/day -108 mm hg 96 valsartan 160 mg/day 112 mm hg 93 valsartan 320 mg/day fi gure 2a,G0000000|G0000000|C0012000|C0005767|C0033095|C0168634|C0332174|G0000000|C1514721|C1442061|G0000000|C0025424|C2699239|C0450371|C0450371|C1442061|C0439422|C4050619|C0178602|C0205195|C1442061|G0000000|C0025424|C0450371|C0450371|C1442061|C0439422|C4050619|C0178602|C0205195|C1442061|G0000000|C0025424|C0450371|G0000000|C0068475|C0450371|C0439422|C1442061|G0000000|C0025424|C0450371|C0068475|C0450371|C0439422|C1442061|G0000000|C0025424|C0450371|C0216784|C1442061|C0439422|C1442061|G0000000|C0025424|C0450371|C0216784|C1442061|C0439422|C4050619|G0000000|C1420849
75,"81 ||| Results ||| 4.32 ||| Adverse events commonly associated with β-blocker use (eg, bradycardia, fatigue, and dizziness) 19,20 were noted with the highest nebivolol dose (40 mg/day, which is rarely used in clinical practice and is associated with a loss of β 1 selectivity",I,adverse events commonly -blocker bradycardia fatigue dizziness 19 20 nebivolol dose 40 mg/day rarely clinical practice loss 1 selectivity,G0000000|C0441471|G0000000|G0000000|C0428977|C0015672|C0012833|C0450371|C0450371|C0068475|C0178602|C0450371|C0439422|C0522498|C0205210|C0237607|C1517945|G0000000|C0036576
76,4 ||| Introduction ||| 1.2 ||| Nebivolol and valsartan are two antihypertensive drugs with proven safety and tolerability.,O,nebivolol valsartan antihypertensive drugs proven safety tolerability,C0068475|C0216784|C0003364|C0013227|C0456369|C0036043|C3274448
77,"62 ||| Results ||| 4.13 ||| A similar fi xed-dose combination eff ect was evident at week 4: for both diastolic and systolic blood pressure, a signifi cant advantage of fi xed-dose combinations 5 and 80 mg/day and 5 and 160 mg/day was noted for all comparisons with their corresponding monotherapies (nebivolol 5 mg/day and valsartan 80 mg/day or 160 mg/day; all p<0·001), except for a diff erence between fi xed-dose combination 5 and 160 mg/day and valsartan 160 mg/day on systolic blood pressure (p=0·11; fi gure 2C and 2D).",O,fi xed-dose combination eff ect evident week 4 diastolic systolic blood pressure signifi advantage fi xed-dose combinations 5 80 mg/day 5 160 mg/day comparisons monotherapies nebivolol 5 mg/day valsartan 80 mg/day 160 mg/day p<0001 diff erence fi xed-dose combination 5 160 mg/day valsartan 160 mg/day systolic blood pressure p=011 fi gure 2c 2d,C4050619|C0178602|C0205195|G0000000|C0013806|C3887511|C0332174|G0000000|C0012000|C0039155|C0005767|C0033095|G0000000|G0000000|C4050619|C0178602|C0453882|G0000000|C0450371|C0439422|G0000000|C1442061|C0439422|C1707455|G0000000|C0068475|G0000000|C0439422|C0216784|C0450371|C0439422|C1442061|C0439422|C0369773|G0000000|G0000000|C4050619|C0178602|C0205195|G0000000|C1442061|C0439422|C0216784|C1442061|C0439422|C0039155|C0005767|C0033095|C0369773|C4050619|G0000000|C4053564|C0043316
78,"16 ||| Introduction ||| 1.14 ||| Random isation was stratifi ed by participation in a biomarker (plasma renin activity and aldosterone concentration) and ABPM substudy and by type 2 diabetes mellitus status, and was done in blocks of 15.",P,random isation stratifi participation biomarker plasma renin activity aldosterone concentration abpm substudy type 2 diabetes mellitus status blocks 15,C0034656|G0000000|G0000000|C0679823|C0005516|C0032105|C0035094|C0205177|C0002006|C0004268|G0000000|G0000000|C0332307|G0000000|C0011847|G0000000|C0449438|C0028778|C0450371
79,21 ||| Introduction ||| 1.19 ||| The mean of the last three values constituted the blood pressure value for the visit.,N,values constituted blood pressure visit,C0042295|G0000000|C0005767|C0033095|C0545082
80,"46 ||| Statistical analysis ||| 3.13 ||| The sponsor was responsible for study monitoring, data management, inventory and distribution of clinical supplies, and data collection and analysis.",N,sponsor responsible study monitoring data management inventory distribution clinical supplies data collection analysis,C1711305|C1273518|C0557651|C0150369|C1511726|C0001554|C0021941|C0520511|C0205210|C0038848|C1511726|C1516698|C0002778
81,"106 ||| Results ||| 4.57 ||| MAW has received speaker, consultant, or research fees from Forest, Boehringer-Ingelheim, Daiichi-Sankyo, Takeda, Medtronic, Boston Scientifi c, AstraZeneca, and Arbor.",I,maw received speaker consultant fees forest boehringer-ingelheim daiichi-sankyo takeda medtronic boston scientifi astrazeneca arbor,G0000000|C1514756|C1707716|C0009817|C0015751|C0086312|C0331792|G0000000|G0000000|G0000000|C0006037|G0000000|G0000000|G0000000
82,"65 ||| Results ||| 4.16 ||| For participants treated with a fi xed-dose combination, changes in pulse rate from baseline to week 8 were similar to those in participants treated with the corresponding nebivolol monotherapies, and in participants taking  valsartan only, mean pulse rate changes were similar to those reported in participants receiving placebo (fi gure 4A).",I,participants treated fi xed-dose combination pulse rate baseline week 8 participants treated nebivolol monotherapies participants valsartan pulse rate reported participants receiving placebo fi gure 4a,C0679646|C1522326|C4050619|C0178602|C0205195|C0232117|C0871208|C0168634|C0332174|G0000000|C0679646|C1522326|C0068475|G0000000|C0679646|C0216784|C0232117|C0871208|C0684224|C0679646|C1514756|C0032042|C4050619|G0000000|C1420849
83,"105 ||| Results ||| 4.56 ||| In the past 36 months, TDG has received personal fees from Forest Laboratories.",I,36 months tdg received personal fees forest laboratories,C0450371|C0439231|C1442760|C1514756|C1519021|C0015751|C0086312|C0022877
84,26 ||| Introduction ||| 1.24 ||| Participants were randomly assigned if adherence to treatment in the last two visits of the single-blind run-in phase averaged 80-120% and diastolic blood pressure measurements,I,participants randomly assigned adherence treatment visits single-blind run-in phase averaged 80-120% diastolic blood pressure measurements,C0679646|G0000000|C1516050|C1510802|C0039798|C0545082|C0242570|C3274438|C0205390|C1510992|C0450371|C0012000|C0005767|C0033095|C0242485
85,"29 ||| Outcomes ||| 2.3 ||| Additional prespecifi ed effi cacy parameters included changes from baseline in mean trough seated diastolic and systolic blood pressure at each visit, changes in pulse rate at week 8, and proportions of participants achieving treatment goal (blood pressure <140/90 mm Hg without type 2 diabetes or <130/80 mm Hg with type 2 diabetes, consistent with JNC7 criteria 2 ) at weeks 4 or 8.",I,additional prespecifi effi cacy parameters included baseline trough seated diastolic systolic blood pressure visit pulse rate week 8 proportions participants achieving treatment goal blood pressure <140/90 mm hg type 2 diabetes <130/80 mm hg type 2 diabetes consistent jnc7 criteria 2 weeks 4 8,C1524062|G0000000|G0000000|C1419788|C0449381|C0332257|C0168634|C0444506|C0277814|C0012000|C0039155|C0005767|C0033095|C0545082|C0232117|C0871208|C0332174|G0000000|C1709707|C0679646|G0000000|C0039798|C0018017|C0005767|C0033095|C1442061|G0000000|C0025424|C0332307|G0000000|C0011847|C1442061|G0000000|C0025424|C0332307|G0000000|C0011847|C0332290|G0000000|C0243161|G0000000|C0439230|G0000000|G0000000
86,"37 ||| Statistical analysis ||| 3.4 ||| The primary effi cacy parameter was analysed using an ANCOVA model, with treatment group and diabetes status as factors and baseline diastolic blood pressure value as a covariate.",P,primary effi cacy parameter analysed ancova model treatment diabetes status factors baseline diastolic blood pressure covariate,C0205225|G0000000|C1419788|C0549193|G0000000|C0814908|C3161035|C0039798|C0011847|C0449438|C1521761|C0168634|C0012000|C0005767|C0033095|G0000000
87,60 ||| Results ||| 4.11 ||| The least-squares mean diff erence in the key secondary endpoint between the fi xed-dose combination and nebivolol ranged from -3·6 (95% CI -5·3 to -1·8; p<0·0001) for the 10 and 160 mg/day fi xed-dose combination compared with nebivolol 10 mg/day to −2·9 (-4·7 to −1·1; p=0·001) for the 20 and 320 mg/day fi xeddose combination compared with nebivolol 40 mg/day.,I,least-squares diff erence key secondary endpoint fi xed-dose combination nebivolol ranged -36 95% ci -53 -18 p<00001 10 160 mg/day fi xed-dose combination compared nebivolol 10 mg/day 29 -47 11 p=0001 20 320 mg/day fi xeddose combination compared nebivolol 40 mg/day,C0023189|G0000000|G0000000|G0000000|C0027627|C2349179|C4050619|C0178602|C0205195|C0068475|C1514721|C0450371|C0450371|C0008107|C0450371|C0450371|C0369773|C0450371|C1442061|C0439422|C4050619|C0178602|C0205195|C1707455|C0068475|C0450371|C0439422|C0450371|C0450371|C0450371|C0369773|C0450371|C1442061|C0439422|C4050619|G0000000|C0205195|C1707455|C0068475|C0450371|C0439422
88,"103 ||| Results ||| 4.54 ||| WC designed the study, analysed data, and revised the manuscript.",N,wc designed study analysed data revised manuscript,C0013123|C1707689|C0557651|G0000000|C1511726|C1527075|C0600659
89,2 |||  ||| 0.2 ||| We assessed the effi cacy and safety of a fi xed-dose combination of a vasodilating β blocker (nebivolol) and an angiotensin II receptor blocker (valsartan) in adults with hypertension.,P,assessed effi cacy safety fi xed-dose combination vasodilating blocker nebivolol angiotensin ii receptor blocker valsartan adults hypertension,C1516048|G0000000|C1419788|C0036043|C4050619|C0178602|C0205195|G0000000|G0000000|C0068475|C0003018|G0000000|C0597357|G0000000|C0216784|C0001675|C0020538
90,22 ||| Introduction ||| 1.20 ||| Seated pulse rate was the mean obtained at the same time the last three seated blood pressure measurements were taken.,I,seated pulse rate time seated blood pressure measurements,C0277814|C0232117|C0871208|C0040223|C0277814|C0005767|C0033095|C0242485
91,"88 ||| Results ||| 4.39 ||| Moreover, available data suggest that both increases in dose and treatment duration for nebivolol",O,data increases dose treatment duration nebivolol,C1511726|C0205217|C0178602|C0039798|C0449238|C0068475
92,57 ||| Results ||| 4.8 ||| The least-squares mean diff erence in the primary endpoint between the fi xed-dose combination and valsartan ranged from -3·7 mm Hg (95% CI -4·8 to -2·6; p<0·0001) for the 10 and 160 mg/day fi xed-dose combination compared with valsartan 160 mg/day to −4·4 (-5·4 to -3·3; p<0·0001) for the 20 and 320 mg/day fi xed-dose combination compared with valsartan 320 mg/day.,I,least-squares diff erence primary endpoint fi xed-dose combination valsartan ranged -37 mm hg 95% ci -48 -26 p<00001 10 160 mg/day fi xed-dose combination compared valsartan 160 mg/day 44 -54 -33 p<00001 20 320 mg/day fi xed-dose combination compared valsartan 320 mg/day,C0023189|G0000000|G0000000|C0205225|C2349179|C4050619|C0178602|C0205195|C0216784|C1514721|C0450371|G0000000|C0025424|C0450371|C0008107|C0450371|C0450371|C0369773|C0450371|C1442061|C0439422|C4050619|C0178602|C0205195|C1707455|C0216784|C1442061|C0439422|C0450371|C0450371|C0450371|C0369773|C0450371|C1442061|C0439422|C4050619|C0178602|C0205195|C1707455|C0216784|C1442061|C0439422
93,56 ||| Results ||| 4.7 ||| The least-squares mean diff erence in the primary endpoint between the fi xed-dose combination and nebivolol ranged from -2·4 mm Hg (95% CI -3·4 to -1·3; p<0·0001) for the 10 and 160 mg/day fi xed-dose combination compared with nebivolol 10 mg/day to −1·2 (-2·3 to −0·1; p=0·030) for the 20 and 320 mg/day fi xeddose combination compared with nebivolol 40 mg/day.,I,least-squares diff erence primary endpoint fi xed-dose combination nebivolol ranged -24 mm hg 95% ci -34 -13 p<00001 10 160 mg/day fi xed-dose combination compared nebivolol 10 mg/day 12 -23 01 p=0030 20 320 mg/day fi xeddose combination compared nebivolol 40 mg/day,C0023189|G0000000|G0000000|C0205225|C2349179|C4050619|C0178602|C0205195|C0068475|C1514721|C0450371|G0000000|C0025424|C0450371|C0008107|C0450371|C0450371|C0369773|C0450371|C1442061|C0439422|C4050619|C0178602|C0205195|C1707455|C0068475|C0450371|C0439422|C0450371|C0450371|C0450371|C0369773|C0450371|C1442061|C0439422|C4050619|G0000000|C0205195|C1707455|C0068475|C0450371|C0439422
94,80 ||| Results ||| 4.31 ||| The absence of a dose response in the fi xed-dose combination groups (fi gure 2) could be attributed to the fl at dose responses for both nebivolol 8 and valsartan.,N,absence dose response fi xed-dose combination fi gure 2 attributed fl dose responses nebivolol 8 valsartan,C0332197|C0178602|C0871261|C4050619|C0178602|C0205195|C4050619|G0000000|G0000000|C0449234|C1708024|C0178602|C0871261|C0068475|G0000000|C0216784
95,1 |||  ||| 0.1 ||| Background The fi xed-dose combination of any two antihypertensive drugs from diff erent drug classes is typically more eff ective in reducing blood pressure than a dose increase of component monotherapy.,O,background fi xed-dose combination antihypertensive drugs diff erent drug classes typically eff ective reducing blood pressure dose increase component monotherapy,C1706907|C4050619|C0178602|C0205195|C0003364|C0013227|G0000000|G0000000|C0013227|C0456387|G0000000|G0000000|G0000000|C0392756|C0005767|C0033095|C0178602|C0442805|C0449432|G0000000
96,"76 ||| Results ||| 4.27 ||| During the 8-week treatment phase, discontinuation rates because of an adverse event ranged from nine of 555 (2%) for those in the 10 and 320 mg/day and 20 and 320 mg/day fi xed-dose combination groups to 22 of 555 (4%) in the nebivolol 40 mg/day group (fi gure 1).",I,8-week treatment phase discontinuation rates adverse event ranged 555 2% 10 320 mg/day 20 320 mg/day fi xed-dose combination 22 555 4% nebivolol 40 mg/day fi gure 1,C0332174|C0039798|C0205390|C0457454|C0871208|G0000000|C0441471|C1514721|C1442061|G0000000|C0450371|C1442061|C0439422|C0450371|C1442061|C0439422|C4050619|C0178602|C0205195|C0450371|C1442061|G0000000|C0068475|C0450371|C0439422|C4050619|G0000000|G0000000
97,"83 ||| Results ||| 4.34 ||| We did not undertake a systematic review per se, but relied on fi ndings from relevant meta-analyses.",O,undertake systematic review se relied fi ndings relevant meta-analyses,G0000000|C0220922|C0282443|C0036919|G0000000|C4050619|G0000000|C2347946|C0920317
98,"77 ||| Results ||| 4.28 ||| The rates of experiencing at least one treatment-emergent adverse event in the safety population were similar across treatment groups: 100 of 277 (36%) in the placebo group, 193 of 555 (35%) in the fi xed-dose combination 10 and 160 mg/day group, 185 of 555 (33%) in the fi xed-dose combination 10 and 320 mg/day group, 189 of 554 (34%) in To our knowledge, this is the fi rst study to assess the effi cacy and safety of a fi xed-dose combination consisting of a β blocker and an angiotensin II receptor blocker in patients with hypertension (panel).",I,rates experiencing treatment-emergent adverse event safety population treatment 100 277 36% placebo 193 555 35% fi xed-dose combination 10 160 mg/day 185 555 33% fi xed-dose combination 10 320 mg/day 189 554 34% knowledge fi rst study assess effi cacy safety fi xed-dose combination consisting blocker angiotensin ii receptor blocker patients hypertension panel,C0871208|C0237607|C0039798|G0000000|C0441471|C0036043|C0032659|C0039798|C1442061|C1442061|C0450371|C0032042|C1442061|C1442061|C0450371|C4050619|C0178602|C0205195|C0450371|C1442061|C0439422|C1442061|C1442061|C0450371|C4050619|C0178602|C0205195|C0450371|C1442061|C0439422|C1442061|C1442061|C0450371|C0376554|C4050619|C1425219|C0557651|C1516048|G0000000|C1419788|C0036043|C4050619|C0178602|C0205195|C0332529|G0000000|C0003018|G0000000|C0597357|G0000000|C0030705|C0020538|C0441833
99,"12 ||| Introduction ||| 1.10 ||| Doses were doubled at the beginning of week 5 to fi xeddose combinations 10 and 160 mg/day, 10 and 320 mg/day, and 20 and 320 mg/day; nebivolol 10 mg/day and 40 mg/day; and valsartan 160 mg/day and 320 mg/day.",I,doses doubled week 5 fi xeddose combinations 10 160 mg/day 10 320 mg/day 20 320 mg/day nebivolol 10 mg/day 40 mg/day valsartan 160 mg/day 320 mg/day,C0178602|C0205173|C0332174|G0000000|C4050619|G0000000|C0453882|C0450371|C1442061|C0439422|C0450371|C1442061|C0439422|C0450371|C1442061|C0439422|C0068475|C0450371|C0439422|C0450371|C0439422|C0216784|C1442061|C0439422|C1442061|C0439422
100,"67 ||| Results ||| 4.18 ||| Across all treatment groups, subgroup analyses revealed no signifi cant interactions between treatment and sex, race, diabetes status, or diastolic blood pressure status at baseline (<median or ≥median) when analysing the primary or key secondary effi cacy endpoints (baseline to week 8 changes in diastolic or systolic blood pressure); however, signifi cant interactions were noted between treatment and Hispanic ethnic origin when analysing diastolic (p=0·004) and systolic blood pressure (p=0·017), and between treatment and age (p=0·018) and treatment and obesity status (p=0·030) when analysing systolic blood pressure.",O,treatment subgroup analyses revealed signifi interactions treatment sex race diabetes status diastolic blood pressure status baseline <median median analysing primary key secondary effi cacy endpoints baseline week 8 diastolic systolic blood pressure signifi interactions treatment hispanic ethnic origin analysing diastolic p=0004 systolic blood pressure p=0017 treatment age p=0018 treatment obesity status p=0030 analysing systolic blood pressure,C0039798|C1079230|C0002778|C0443289|G0000000|C1704675|C0039798|C0009253|C0034510|C0011847|C0449438|C0012000|C0005767|C0033095|C0449438|C0168634|C0549183|C0549183|G0000000|C0205225|G0000000|C0027627|G0000000|C1419788|C2349179|C0168634|C0332174|G0000000|C0012000|C0039155|C0005767|C0033095|G0000000|C1704675|C0039798|C0086409|C0015031|C0079946|G0000000|C0012000|C0369773|C0039155|C0005767|C0033095|C0369773|C0039798|C0001779|C0369773|C0039798|C0028754|C0449438|C0369773|G0000000|C0039155|C0005767|C0033095
101,"25 ||| Introduction ||| 1.23 ||| After a 1-week screening period, participants entered a 6-week single-blind placebo run-in phase, which was followed by an 8-week double-blind treatment period and a 1-week double-blind down-titration phase.",I,1-week screening period participants entered 6-week single-blind placebo run-in phase 8-week double-blind treatment period 1-week double-blind down-titration phase,C0332174|C0220908|C0439531|C0679646|C1521975|C0332174|C0242570|C0032042|C3274438|C0205390|C0332174|C0013072|C0039798|C0439531|C0332174|C0013072|C0162621|C0205390
102,69 ||| Results ||| 4.20 ||| The eff ects of the fi xed-dose combination 20 and 320 mg/day versus placebo were clinically signifi cant across a range of patient phenotypes (fi gure 5).,N,eff ects fi xed-dose combination 20 320 mg/day versus placebo clinically signifi range patient phenotypes fi gure 5,G0000000|C0013806|C4050619|C0178602|C0205195|C0450371|C1442061|C0439422|G0000000|C0032042|G0000000|G0000000|C1514721|C0030705|C0031437|C4050619|G0000000|G0000000
103,"28 ||| Outcomes ||| 2.2 ||| Other secondary effi cacy parameters were changes from baseline in mean trough seated diastolic and systolic blood pressure at week 4 and changes in 24-h ABPM values for diastolic and systolic blood pressure from baseline to week 8 for participants assigned to the fi xeddose combination of 20 and 320 mg/day versus 40 mg/day nebivolol and 320 mg/day valsartan; diastolic blood pressure responder rates at week 8 at levels less than 90 mm Hg and less than 80 mm Hg, and systolic blood pressure responder rates at week 8 at levels less than 140 mm Hg and less than 130 mm Hg (20 and 320 mg/day fi xed-dose combination versus nebivolol 40 mg/day and valsartan 320 mg/day).",I,secondary effi cacy parameters baseline trough seated diastolic systolic blood pressure week 4 24-h abpm values diastolic systolic blood pressure baseline week 8 participants assigned fi xeddose combination 20 320 mg/day versus 40 mg/day nebivolol 320 mg/day valsartan diastolic blood pressure responder rates week 8 levels 90 mm hg 80 mm hg systolic blood pressure responder rates week 8 levels 140 mm hg 130 mm hg 20 320 mg/day fi xed-dose combination versus nebivolol 40 mg/day valsartan 320 mg/day,C0027627|G0000000|C1419788|C0449381|C0168634|C0444506|C0277814|C0012000|C0039155|C0005767|C0033095|C0332174|G0000000|C0450371|G0000000|C0042295|C0012000|C0039155|C0005767|C0033095|C0168634|C0332174|G0000000|C0679646|C1516050|C4050619|G0000000|C0205195|C0450371|C1442061|C0439422|G0000000|C0450371|C0439422|C0068475|C1442061|C0439422|C0216784|C0012000|C0005767|C0033095|G0000000|C0871208|C0332174|G0000000|C0441889|C0450371|G0000000|C0025424|C0450371|G0000000|C0025424|C0039155|C0005767|C0033095|G0000000|C0871208|C0332174|G0000000|C0441889|C1442061|G0000000|C0025424|C1442061|G0000000|C0025424|C0450371|C1442061|C0439422|C4050619|C0178602|C0205195|G0000000|C0068475|C0450371|C0439422|C0216784|C1442061|C0439422
104,"64 ||| Results ||| 4.15 ||| At week 8, blood pressure control rates were signifi cantly greater in the fi xed-dose combination 20 and 320 mg/day group (285 of 550 [52%]) than in the valsartan 320 mg/day group (195 of 547 [36%]; p<0·0001) and the nebivolol 40 mg/day group (247 of 547 [45%]; p=0·023; fi gure 3C).",I,week 8 blood pressure control rates signifi cantly fi xed-dose combination 20 320 mg/day 285 550 52% valsartan 320 mg/day 195 547 36% p<00001 nebivolol 40 mg/day 247 547 45% p=0023 fi gure 3c,C0332174|G0000000|C0005767|C0033095|C0243148|C0871208|G0000000|G0000000|C4050619|C0178602|C0205195|C0450371|C1442061|C0439422|C1442061|C1442061|C0450371|C0216784|C1442061|C0439422|C1442061|C1442061|C0450371|C0369773|C0068475|C0450371|C0439422|C1442061|C1442061|C0450371|C0369773|C4050619|G0000000|C4053564
105,"5 ||| Introduction ||| 1.3 ||| Reasons for exclusion included secondary hypertension; systolic blood pressure at least 180 mm Hg or diastolic blood pressure at least 110 mm Hg; treatment with more than four antihypertensive drugs (including components of fi xeddose combinations); contraindication to discontinuation of present antihypertensive treatment; upper arm circumference greater than 42 cm; presence of coronary artery disease, reactive airway disease, chronic obstructive pulmonary disease, second-degree or third-degree heart block or sick sinus syndrome, heart failure, hypertensive retinopathy (Keith-Wagener-Barker grade III or IV), type 1 diabetes, poorly controlled type 2 diabetes (glycated haemoglobin ≥8%), uncontrolled thyroid disease within 3 months of screening, infl ammatory bowel disease or active gastritis, pancreatitis, or renal impairment (estimated glomerular fi ltration rate <60 mL/min); and pregnancy or breastfeeding.",P,reasons exclusion included secondary hypertension systolic blood pressure 180 mm hg diastolic blood pressure 110 mm hg treatment antihypertensive drugs including components fi xeddose combinations contraindication discontinuation antihypertensive treatment upper arm circumference 42 cm presence coronary artery disease reactive airway disease chronic obstructive pulmonary disease second-degree third-degree heart block sick sinus syndrome heart failure hypertensive retinopathy keith-wagener-barker grade iii iv type 1 diabetes controlled type 2 diabetes glycated haemoglobin 8% uncontrolled thyroid disease 3 months screening infl ammatory bowel disease active gastritis pancreatitis renal impairment estimated glomerular fi ltration rate <60 ml/min pregnancy breastfeeding,C0392360|C0680251|C0332257|C0027627|C0020538|C0039155|C0005767|C0033095|C1442061|G0000000|C0025424|C0012000|C0005767|C0033095|C1442061|G0000000|C0025424|C0039798|C0003364|C0013227|C0332257|C0449432|C4050619|G0000000|C0453882|C0522473|C0457454|C0003364|C0039798|C1282910|C0446516|C0332520|C0450371|G0000000|C0150312|C0018787|C0003842|C0012634|C0205332|C0178987|C0012634|C0205191|C0549186|C0024109|C0012634|C0443298|C0443323|C0018787|C0028778|C0221423|C0016169|C0039082|C0018787|C0231174|C0857121|C0035309|G0000000|C0441800|C0439070|C0022326|C0332307|G0000000|C0011847|C2587213|C0332307|G0000000|C0011847|C3666909|C0019046|G0000000|C0205318|C0040132|C0012634|G0000000|C0439231|C0220908|G0000000|G0000000|C0021853|C0012634|C0205177|C0017152|C0030305|C0022646|C0221099|C0750572|C0022663|C4050619|G0000000|C0871208|C0450371|C0439445|C0032961|C0006147
106,79 ||| Results ||| 4.30 ||| Other nebivolol and valsartan fi xed-dose combinations examined resulted in signifi cantly greater reductions from baseline in diastolic and systolic blood pressure compared with their monotherapy components.,O,nebivolol valsartan fi xed-dose combinations examined signifi cantly reductions baseline diastolic systolic blood pressure compared monotherapy components,C0068475|C0216784|C4050619|C0178602|C0453882|C0332128|G0000000|G0000000|C0301630|C0168634|C0012000|C0039155|C0005767|C0033095|C1707455|G0000000|C0449432
107,"52 ||| Results ||| 4.3 ||| Consent withdrawal was the most frequent reason for discontinuation in all active-treatment groups, with the exception of nebivolol 40 mg/day (adverse events) and nebivolol 10 mg/day (consent withdrawal; adverse events; fi gure 1).",N,consent withdrawal frequent reason discontinuation active-treatment exception nebivolol 40 mg/day adverse events nebivolol 10 mg/day consent withdrawal adverse events fi gure 1,C1511481|C2349954|C0332183|C0392360|C0457454|C1704532|C1554961|C0068475|C0450371|C0439422|G0000000|C0441471|C0068475|C0450371|C0439422|C1511481|C2349954|G0000000|C0441471|C4050619|G0000000|G0000000
108,"90 ||| Results ||| 4.41 ||| Several factors that might be useful when selecting drugs for combination therapy include absence of a pharmacokinetic interaction, reduction in long-term adverse cardiovascular incidences, and mechanisms of action that target diff erent disease pathways.",N,factors selecting drugs combination therapy absence pharmacokinetic interaction reduction long-term adverse cardiovascular incidences mechanisms action target diff erent disease pathways,C1521761|C1707391|C0013227|C0205195|C0039798|C0332197|C0201734|C1704675|C0301630|C0443252|G0000000|C0007226|C0021149|C0441712|C0441472|C1521840|G0000000|G0000000|C0012634|C1704259
109,82 ||| Results ||| 4.33 ||| Systematic review,N,systematic review,C0220922|C0282443
